Company news

Neurotech International Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Successful Landmark Study in Paediatric ASD

April 4, 2022

Notification regarding unquoted securities - NTI

March 10, 2022

Neurotech International: Proposed issue of securities - NTI

March 3, 2022

Appointment of Chief Executive Officer

March 2, 2022

Application for quotation of securities - NTI

January 24, 2022

Response to ASX Query Letter

October 13, 2021

Appendix 4E and Annual Report

August 29, 2021

Quarterly Report and Appendix 4C

July 29, 2021

Neurotech Expands License with Dolce Cann Global

March 1, 2021

Successful Completion of In Vitro Studies

December 20, 2020

Further Success with Preliminary In-vitro Studies

November 29, 2020

Voluntary Suspension

November 26, 2020

Interim Results and Capital Raising

November 1, 2020

Response to ASX Price and Volume Query

October 22, 2020

Neurotech Proceeds to in vitro trials after Positive Results

September 6, 2020

Response to ASX price query

August 21, 2020

Pause in Trading

August 20, 2020

NTI Secures Option to Cannabis Strains Targeting Autism

July 3, 2020

Mente receives CE Mark renewal for use with ASD Children

April 8, 2020

Response to Appendix 4C Query

February 17, 2020

Cancellation of Mente Device from Australian TGA Register

January 27, 2020

Appendix 4E and Annual Report to Shareholders

August 30, 2019

Quarterly Update & Appendix 4C

July 31, 2019

Pause In Trading

May 29, 2019

Quarterly Activities and Cashflow Report

April 30, 2019

Response to ASX Price Query

April 23, 2019

Dr Adrian Attard Trevisan

March 26, 2019

Appendix 4D and 31 December 2018 Half Year Report

February 28, 2019

Renounceable pro-rata rights issue

February 24, 2019

Supplementary Prospectus

February 7, 2019

Prospectus - Renounceable Rights Issue

January 29, 2019

Investor Presentation

January 28, 2019

Appointment of Peter Griffiths as CEO

November 25, 2018

New Appointments

October 22, 2018

Quarterly report

October 18, 2018

Shipment of Mente Autism devices

October 3, 2018

Mente Autism - FDA Clearance Application

October 1, 2018

First Shipments of Mente Autism

August 9, 2018

Quarterly report and Appendix 4C

July 31, 2018

US Clinical Trial Results Published

July 8, 2018

Mente Autism Approval From Italcert

June 4, 2018

Appendix 4D and 31 December 2017 Half Year Financial Report

February 28, 2018

Indian Distribution Agreement

January 17, 2018

Design Agreement with eemagine

November 27, 2017

Capital Raising Completed

October 15, 2017

Response to ASX Query

October 3, 2017

Clinical Trial Preliminary Outcomes

September 26, 2017

Distributor Update

September 13, 2017

Appendix 4E

September 1, 2017

Italian Distributor Update

August 20, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 34 decks. Every deck is listed under its year.